The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?

Journal of Neuroinflammation

Rosana L Pagano²  Erich T Fonoff¹  Patrícia SS Lopes²  Guilherme D Silva² 

[1] Division of Functional Neurosurgery, Department of Neurology, University of São Paulo School of Medicine, Rua Dr Ovídio Pires de Campos, 785, São Paulo, 01060-970, SP, Brazil;Laboratory of Neuromodulation and Experimental Pain, Hospital Sírio Libanês, Rua Coronel Nicolau dos Santos, 69, São Paulo, 01308-060, SP, Brazil

关键词: Rats;    Spinal cord;    Neuroinflammation;    Cannabinoids;    Glia;    Neuropathic pain;    Epidural stimulation;    Motor cortex;   

Others  :  1133205
DOI  :  10.1186/s12974-014-0216-1

 received in 2014-09-09, accepted in 2014-12-05,  发布年份 2015

【 摘 要 】

Background

Motor cortex stimulation (MCS) is an effective treatment in neuropathic pain refractory to pharmacological management. However, analgesia is not satisfactorily obtained in one third of patients. Given the importance of understanding the mechanisms to overcome therapeutic limitations, we addressed the question: what mechanisms can explain both MCS effectiveness and refractoriness? Considering the crucial role of spinal neuroimmune activation in neuropathic pain pathophysiology, we hypothesized that modulation of spinal astrocyte and microglia activity is one of the mechanisms of action of MCS.

Methods

Rats with peripheral neuropathy (chronic nerve injury model) underwent MCS and were evaluated with a nociceptive test. Following the test, these animals were divided into two groups: MCS-responsive and MCS-refractory. We also evaluated a group of neuropathic rats not stimulated and a group of sham-operated rats. Some assays included rats with peripheral neuropathy that were treated with AM251 (a cannabinoid antagonist/inverse agonist) or saline before MCS. Finally, we performed immunohistochemical analyses of glial cells (microglia and astrocytes), cytokines (TNF-α and IL-1β), cannabinoid type 2 (CB2), μ-opioid (MOR), and purinergic P2X4 receptors in the dorsal horn of the spinal cord (DHSC).

Findings

MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury. Spinal MOR staining was also inhibited upon MCS. Pre-treatment with AM251 blocked the effects of MCS, including the inhibitory mechanism on cells. Finally, MCS-refractory animals showed similar CB2, but higher P2X4 and MOR staining intensity in the DHSC in comparison to MCS-responsive rats.

Conclusions

These results indicate that MCS induces analgesia through a spinal anti-neuroinflammatory effect and the activation of the cannabinoid and opioid systems via descending inhibitory pathways. As a possible explanation for MCS refractoriness, we propose that CB2 activation is compromised, leading to cannabinoid resistance and consequently to the perpetuation of neuroinflammation and opioid inefficacy.

【 授权许可】

   
2015 Silva et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al.: A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
• [2]Besson JM: The neurobiology of pain. Lancet 1999, 353:1610-1615.
• [3]Woolf CJ, Salter MW: Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765-1769.
• [4]Zimmermann M: Pathobiology of neuropathic pain. Eur J Pharmacol 2001, 429:23-37.
• [5]Woolf CJ, Mannion RJ: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
• [6]Austin PJ, Moalem-Taylor G: The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 2010, 229:26-50.
• [7]Garden G, Moller T: Microglia biology in health and disease. J Neuroimmune Pharmacol 2006, 1:127-137.
• [8]Wei F, Dubner R, Ren K: Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 2007, 27:6006-6018.
• [9]Vallejo R, Tilley DM, Vogel L, Beyamin R: The role of glia and immune system in the development and maintenance of neuropathic pain. Pain Pract 2010, 10:167-184.
• [10]Mackie K: Cannabinoid receptors as therapeutic targets. Annu Ver Pharmacol Toxicol 2006, 46:101-122.
• [11]Stella N: Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 1:244-253.
• [12]Beggs S, Trang T, Salter M: P2X4R microglia drive neuropathic pain. Nat Neurosci 2012, 15:1068-1073.
• [13]Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S: Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochir Suppl 1991, 52:137-139.
• [14]Nguyen JP, Lefaucheur JP, Decq P, Uchiyama T, Carpentier A, Fontaine D, et al.: Chronic motor cortex stimulation in the treatment of central and neuropathic pain. Correlations between clinical, electrophysiological and anatomical data. Pain 1999, 82:245-251.
• [15]Rasche D, Ruppolt M, Stippich C, Unterberg A, Tronnier VM: Motor cortex stimulation for long-term relief of chronic neuropathic pain: a 10 year experience. Pain 2006, 121:43-52.
• [16]Cruccu G, Aziz T, Garcia-Larrea L, Hansson P, Jensen T, Lefaucheur J, et al.: EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007, 14:952-970.
• [17]Velasco F, Argüelles C, Carrillo-Ruiz JD, Castro G, Velasco AL, Jiménez F, et al.: Efficacy of motor cortex stimulation in the treatment of neuropathic pain: a randomized double-blind trial. J Neurosurg 2008, 108:698-706.
• [18]Fontaine D, Hamani C, Lozano A: Efficacy and safety of motor cortex stimulation for chronic neuropathic pain: critical review of the literature. J Neurosurg 2009, 110:251-256.
• [19]Fagundes-Pereyra WJ, Teixeira MJ, Reyns N, Touzet G, Dantas S, Blond S: Motor cortex electric stimulation for the treatment of neuropathic pain. Arq Neuropsiquiatr 2010, 68:923-929.
• [20]Nguyen JP, Lefaucher JP, Le Guerinel C: Motor cortex stimulation in the treatment of central and neuropathic pain. Arch Med Res 2000, 31:263-265.
• [21]Garcia-Larrea L, Peyron R: Motor cortex stimulation for neuropathic pain: from phenomenology to mechanisms. Neuroimage 2007, 37(Suppl 1):S71-S79.
• [22]Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al.: Motor cortex stimulation for pain control induces changes in the endogenous opioid system. Neurology 2007, 69:827-834.
• [23]Peyron R, Faillenot I, Mertens P, Laurent B, Garcia-Larrea L: Motor cortex stimulation in neuropathic pain. Correlations between analgesic effect and hemodynamic changes in the brain. A PET study. Neuroimage 2007, 34:310-321.
• [24]Fonoff ET, Dale CS, Pagano RL, Paccola CC, Ballester G, Teixeira MJ, et al.: Antinociception induced by epidural motor cortex stimulation in naive conscious rats is mediated by the opioid system. Behav Brain Res 2009, 196:63-70.
• [25]Viisanen H, Pertovaara A: Roles of the rostroventromedial medulla and the spinal 5-HT(1A) receptor in descending antinociception induced by motor cortex stimulation in the neuropathic rat. Neurosci Lett 2010, 476:133-137.
• [26]Pagano RL, Fonoff ET, Dale CS, Ballester G, Teixeira MJ, Britto LR: Motor cortex stimulation inhibits thalamic sensory neurons and enhances activity of PAG neurons: possible pathways for antinociception. Pain 2012, 153:2359-2369.
• [27]Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al.: Brain opioid receptor density predicts motor cortex stimulation efficacy for chronic pain. Pain 2013, 154:2563-2568.
• [28]Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
• [29]Bennett GJ, Xie YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
• [30]Fonoff ET, Pereira JP Jr, Camargo LV, Dale CS, Pagano RL, Ballester G, et al.: Functional mapping of the motor cortex of rat using transdural electrical stimulation. Behav Brain Res 2009, 202:138-141.
• [31]Pagano RL, Assis DV, Clara JA, Alves AS, Dale CS, Teixeira MJ, et al.: Transdural motor cortex stimulation reverses neuropathic pain in rats: a profile of neuronal activation. Eur J Pain 2011, 15:268.e1-268.e14.
• [32]Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW: Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006, 147:281-288.
• [33]Randall LO, Selitto JJ: A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn 1957, 111:409-419.
• [34]Montgomery DL: Astrocyte: form, functions, and roles in disease. Vet Pathol 1994, 31:145-167.
• [35]Pekny M, Nilsson M: Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
• [36]Smith HS: Activated microglia in nociception. Pain Physician 2010, 13:295-304.
• [37]Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
• [38]Marchand F, Perretti M, McMahon SB: Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
• [39]Dai ZK, Lin TC, Liou JC, Cheng KI, Chen JY, Chu LW, et al.: Xanthine derivative KMUP-1 reduces inflammation and hyperalgesia in a bilateral chronic constriction injury model by suppressing MAPK and NFκB activation. Mol Pharm 2014, 11:1621-1631.
• [40]Hu C, Zhang G, Zhao YT: Fucoidan attenuates the existing allodynia and hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 2014, 571:66-71.
• [41]Zhou C, Shi X, Huang H, Zhu Y, Wu Y: Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury. Anesth Analg 2014, 118:1090-1096.
• [42]Lau LT, Yu AC: Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury. J Neurotrauma 2001, 18:351-359.
• [43]Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I: Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol 2006, 2:259-269.
• [44]Gao YJ, Ji RR: Targeting astrocyte signaling for chronic pain. Neurotherapeutics 2010, 7:482-493.
• [45]Walter L, Stella N: Cannabinoids and neuroinflammation. Br J Pharmacol 2004, 141:775-785.
• [46]Rani Sagar D, Burston JJ, Woodhams SG, Chapman V: Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci 2012, 367:3300-3311.
• [47]Luongo L, Maione S, Di Marzo V: Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. Eur J Neurosci 2014, 39:401-408.
• [48]Racz I, Nadal X, Alferink J, Baños JE, Rehnelt J, Martín M, et al.: Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008, 28:12125-12135.
• [49]Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, et al.: 1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis 2010, 37:177-185.
• [50]New DC, Wong YH: BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett 2003, 536:157-160.
• [51]Dossou KS, Devkota KP, Kavanagh PV, Beutler JA, Egan JM, Moaddel R: Development and preliminary validation of a plate-based CB1/CB2 receptor functional assay. Anal Biochem 2013, 437:138-143.
• [52]Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O’Donnell D: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003, 17:2750-2754.
• [53]Ashton JC, Glass M: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007, 5:73-80.
• [54]Kao SC, Zhao X, Lee CY, Atianjoh FE, Gauda EB, Yaster M, et al.: Absence of μ opioid receptor mRNA expression in astrocytes and microglia of rat spinal cord. Neuroreport 2012, 23:378-384.
• [55]Puffenbarger RA, Boothe AC, Cabral GA: Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000, 29:58-69.
• [56]Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK: Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005, 49:211-219.
• [57]Besson JM, Chaouch A: Peripheral and spinal mechanisms of nociception. Physiol Rev 1987, 67:67-186.
• [58]Dickenson AH: Spinal cord pharmacology of pain. Br J Anaesth 1995, 75:193-200.
• [59]Trafton JA, Abbadie C, Marek K, Basbaum AI: Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation. J Neurosci 2000, 20:8578-8584.
• [60]Smith RR, Martin-Schild S, Kastin AJ, Zadina JE: Decreases in endomorphin-2-like immunoreactivity concomitant with chronic pain after nerve injury. Neuroscience 2001, 105:773-778.
• [61]Smith HS: Opioids and neuropathic pain. Pain Physician 2012, 15(3 Suppl):ES93-ES110.
• [62]Truong W, Cheng C, Xu QG, Li XQ, Zochodne DW: Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol 2003, 53:366-375.
• [63]Przewlocki R, Przewlocka B: Opioids in neuropathic pain. Curr Pharm Des 2005, 11:3013-3025.
• [64]Romero-Sandoval A, Nutile-McMenemy N, DeLeo JÁ: Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008, 108:722-734.
• [65]Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, et al.: Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011, 162:428-440.
• [66]Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al.: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424:778-783.
• [67]Nasu-Tada K, Koizumi S, Tsuda M, Kunifusa E, Inoue K: Possible involvement of increase in spinal fibronectin following peripheral nerve injury in upregulation of microglial P2X4, a key molecule for mechanical allodynia. Glia 2006, 53:769-775.
• [68]Lantero A, Tramullas M, Pílar-Cuellar F, Valdizán E, Santillán R, Roques BP, et al.: TGF-β and opioid receptor signaling crosstalk results in improvement of endogenous and exogenous opioid analgesia under pathological pain conditions. J Neurosci 2014, 34:5385-5395.
• [69]Desroches J, Bouchard JF, Gendron L, Beaulieu P: Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience 2014, 261:23-42.
• [70]Chiou RJ, Chang CW, Kuo CC: Involvement of the periaqueductal gray in the effect of motor cortex stimulation. Brain Res 2013, 1500:28-35.
• [71]Senapati AK, Huntington PJ, Peng YB: Spinal dorsal horn neuron response to mechanical stimuli is decreased by electrical stimulation of the primary motor cortex. Brain Res 2005, 1036:173-179.